ドキソルビシンの世界市場 - 市場規模、シェア、成長分析：タイプ別 - 業界予測（2023年～2030年）

世界のドキソルビシンの市場規模は2021年に9億米ドル、2022年に11億米ドルとなりました。同市場は、予測期間中（2023年～2030年）に5.8%のCAGRで拡大し、2030年には17億米ドルに達すると予測されています。

世界のドキソルビシン市場は著しい成長を遂げており、今後も上昇基調が続くと予想されます。ドキソルビシンは広く使用されている化学療法薬で、主に乳がん、卵巣がん、肺がん、軟部肉腫など、さまざまな種類のがんの治療に用いられています。この市場を牽引しているのは、世界のがん罹患率の増加と、効果的ながん治療オプションに対する需要の高まりです。さらに、ドラッグデリバリーシステムや併用療法の進歩が市場の成長をさらに後押ししています。しかし、治療費の高騰、薬剤の副作用の可能性、代替療法の出現といった課題も抱えています。こうした課題にもかかわらず、個別化医療や標的療法への注目が高まっていることから、ドキソルビシン市場には今後数年間で有利なビジネスチャンスが生まれると期待されています。

世界のドキソルビシン市場の促進要因の1つは、世界のがんの有病率の増加です。ドキソルビシンは、乳がん、肺がん、白血病など、さまざまな種類のがんの治療に広く使用されている化学療法薬です。がん罹患率の上昇と効果的ながん治療に対するニーズの高まりが、ドキソルビシンの需要を牽引しています。さらに、ドキソルビシンの新たな適応症や製剤を探索するための研究開発が進行中であることも、市場の成長に寄与しています。

世界のドキソルビシン市場の抑制要因の1つは、使用に伴う副作用の可能性です。ドキソルビシンは心毒性、骨髄抑制、胃腸障害など様々な副作用を引き起こすことが知られています。これらの副作用はその使用を制限し、薬剤の投与に課題をもたらす可能性があります。ヘルスケアプロバイダーはドキソルビシンを投与されている患者を注意深くモニターし、これらの副作用を最小限に抑え、管理するために必要な予防措置を講じる必要があります。さらに、代替治療の選択肢や標的療法の出現も、場合別はドキソルビシンの需要に影響を与える可能性があります。

当レポートは、世界のドキソルビシン市場について調査し、市場の概要とともに、タイプ別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

親市場分析

市場規模

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題

主要な市場の洞察

• 技術分析
• 価格分析
• サプライチェーン分析
• バリューチェーン分析
• 市場のエコシステム
• IP分析
• 動向分析
• スタートアップ分析
• 原材料分析
• イノベーションマトリックス
• パイプライン製品分析
• マクロ経済指標
• トップ投資分析
• 主な成功要因
• 競合の程度

市場力学と見通し

• 市場力学
• 促進要因
• 機会
• 抑制要因
• 課題
• 規制状況
• ポーター分析

世界のドキソルビシン市場、タイプ別

• 市場概要
• 従来型ドキソルビシン製剤とリポソームドキソルビシン製剤

世界のドキソルビシン市場、地域別

• 市場概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

競合情勢

• 主要企業プロファイル
  • Pfizer
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aspen Pharmacare Holdings Limited
  • Baxter International Inc.
  • Mylan N.V.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Accord Healthcare Ltd
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG
  • Kyowa Kirin Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila
  • Actavis Generics
  • Wockhardt Ltd.
  • Sandoz International GmbH

Global Doxorubicin Market size was valued at USD 0.9 billion in 2021 and is poised to grow from USD 1.1 billion in 2022 to USD 1.7 billion by 2030, growing at a CAGR of 5.8% in the forecast period (2023-2030).

The global doxorubicin market is experiencing significant growth and is expected to continue its upward trajectory in the coming years. Doxorubicin is a widely used chemotherapy drug that is primarily used in the treatment of various types of cancers, including breast cancer, ovarian cancer, lung cancer, and soft tissue sarcomas. The market is driven by the increasing prevalence of cancer worldwide and the growing demand for effective cancer treatment options. Additionally, advancements in drug delivery systems and combination therapies are further fueling the market growth. However, the market is also faced with challenges such as the high cost of treatment, potential side effects of the drug, and the emergence of alternative therapies. Despite these challenges, the increasing focus on personalized medicine and targeted therapies is expected to create lucrative opportunities for the Doxorubicin market in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Doxorubicin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Doxorubicin Market Segmental Analysis

The global doxorubicin market is segmented by type and region. Based on type, the market can be segmented into conventional doxorubicin formulation and liposomal doxorubicin formulations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Doxorubicin Market

Increasing Prevalence Of Cancer Worldwide

• One driver of the global doxorubicin market is the increasing prevalence of cancer worldwide. Doxorubicin is a widely used chemotherapy drug for the treatment of various types of cancer, including breast cancer, lung cancer, and leukemia. The rising incidence of cancer cases, coupled with the growing need for effective cancer treatments, drives the demand for Doxorubicin. Additionally, ongoing research and development activities to explore new indications and formulations of Doxorubicin contribute to market growth.

Restraints in the Global Doxorubicin Market

Potential Side Effects Associated With Its Use

• One restraint of the global doxorubicin market is the potential side effects associated with its use. Doxorubicin is known to cause various adverse effects, including cardiotoxicity, myelosuppression, and gastrointestinal issues. These side effects can limit its use and pose challenges in the administration of the drug. Healthcare providers need to carefully monitor patients receiving Doxorubicin and take necessary precautions to minimize and manage these side effects. Furthermore, the availability of alternative treatment options and the emergence of targeted therapies may also impact the demand for Doxorubicin in certain cases.

Market Trends of the Global Doxorubicin Key

• One key market trend in the global doxorubicin market is the increasing adoption of combination therapies. Doxorubicin, a widely used chemotherapy drug, is often used in combination with other drugs or treatment modalities to enhance its effectiveness and reduce potential side effects. Combination therapies can help to overcome drug resistance, improve response rates, and increase overall survival rates for patients. Healthcare providers and researchers are exploring various combination regimens involving Doxorubicin, such as combining it with targeted therapies or immunotherapies, to achieve better treatment outcomes. This trend highlights the ongoing efforts to optimize Doxorubicin's therapeutic potential and improve the overall management of cancer patients.

Table of Contents

• Executive Summary
  • Market Overview
  • Wheel of Fortune
• Research Methodology
  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations
• Parent Market Analysis
  • Market Overview
  • Market Size
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
• Key Market Insights
  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition
• Market Dynamics & Outlook
  • Market Dynamics
• Drivers
• Opportunities
• Restraints
• Challenges
  • Regulatory Landscape
  • Porters Analysis
• Competitive rivalry
• Threat of Substitute Products
• Bargaining Power of Buyers
• Threat of New Entrants
• Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
• Political Impact
• Economic Impact
• Social Impact
• Technical Impact
• Environmental Impact
• Legal Impact
• Global Doxorubicin Market by Type
  • Market Overview
  • Conventional Doxorubicin formulation and liposomal Doxorubicin formulations
• Global Doxorubicin Market Size by Region
  • Market Overview
  • North America
• USA
• Canada
  • Europe
• Germany
• Spain
• France
• UK
• Rest of Europe
  • Asia Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
  • Latin America
• Brazil
• Rest of Latin America
  • Middle East & Africa (MEA)
• GCC Countries
• South Africa
• Rest of MEA
• Competitive Landscape
  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
• By Development
• By Company
• By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021
• Key Company Profiles
  • Pfizer (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Johnson & Johnson (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Teva Pharmaceutical Industries Ltd. (Israel)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Sanofi (France)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Novartis AG (Switzerland)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Sun Pharmaceutical Industries Ltd. (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Aspen Pharmacare Holdings Limited (South Africa)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Baxter International Inc. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Mylan N.V. (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Cipla Limited (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Accord Healthcare Ltd. (United Kingdom)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Hikma Pharmaceuticals PLC (Jordan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Fresenius Kabi AG (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Kyowa Kirin Co., Ltd. (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Zydus Cadila (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Actavis Generics (United States)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Wockhardt Ltd. (India)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments
  • Sandoz International GmbH (Germany)
• Company Overview
• Business Segment Overview
• Financial Updates
• Key Developments